Results 91 to 100 of about 178,517 (322)
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Molecular Oncology, EarlyView.In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
Apollo Medicine, 2021 Recent developments in the management of multiple sclerosis (MS) are ushering in a new era in MS treatment. The novel therapeutic disease-modifying agents that have been recently approved for the treatment of MS are B-cell therapies and various ...
Anshu Rohatgi, Neha Pandita
doaj +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation
Frontiers in Immunology, 2018 Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara Roman-Garcia +5 more
doaj +1 more source
Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]
, 2015 Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte +23 more
core
Bruton Tyrosine Kinase Inhibitors
The Cancer Journal, 2019 Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of ...
openaire +3 more sources
American Journal of Hematology, EarlyView.Mixed autoimmune hemolytic anemia (AIHA) is a rare condition characterized by the presence of both warm and cold autoantibodies, often leading to severe, treatment‐resistant hemolysis. In this systematic review of 81 patients across 35 studies, the median age was 45 years with a notable female predominance.
Jeremy W. Jacobs +12 more
wiley +1 more source
Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
Current Oncology Reports, 2021 The purpose of this review is to summarize the epidemiology, mechanisms, and management of cardiovascular complications of Bruton’s Tyrosine Kinase inhibitors (BTKIs).
M. Sestier +3 more
semanticscholar +1 more source
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Annals of Neurology, EarlyView.The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr. +2 more
wiley +1 more source
Advances in RheumatologyBruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase, plays a remarkable role in the transmission and amplification of extracellular signals to intracellular signaling pathways.
Gita Manzari Tavakoli +2 more
doaj +1 more source